Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01352845 · ClinicalTrials.gov registry record · Phase 3
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,301
- Enrollment target
NCT01352845: Completed Phase 3 study, sponsored by Pfizer.
NCT01352845 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 3,301 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (328% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01352845, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,301 participants
- Enrollment target
Study Summary
This study is looking at a new vaccine that might prevent meningococcal disease, and will study the immune response elicited by this vaccine when given to healthy young adults. The study will also look at the safety of the new vaccine as well as how it is tolerated.
Primary Outcome
Here, N signifies participants with valid and determinate hSBA titers for given strain at specified time point. This outcome measure was planned to be analyzed for Group 1 only.
Interventions
- OTHER Placebo
- BIOLOGICAL rLP2086
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,301 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-02 |
| Phase | Phase 3 |
What the finished NCT01352845 record still lists
NCT01352845 is an interventional study that assigns participants to a tested intervention. Its 3,301 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (328% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01352845 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01352845 about?
NCT01352845 is a clinical study titled "A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.". This study is looking at a new vaccine that might prevent meningococcal disease, and will study the immune response elicited by this vaccine when given to healthy young adults. The study will also look at the safety of the new vaccine as well as how it is tolerated.
What is the current status of trial NCT01352845?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,301 participants. The study started on 2013-05. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01352845?
The interventions under investigation include: Placebo (OTHER), rLP2086 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01352845?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01352845's enrollment target sits among peer trials
3,301 72nd of 2000 higher than 1,929 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07214610 · 3,300 participants · NA
Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study
- NCT03674307 · 3,306 participants · NA
Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
- NCT06815536 · 3,291 participants
Master Protocol for Evaluating Multiple Infection Diagnostics for Ciprofloxacin-Resistant Neisseria Gonorrhoeae
- NCT06543446 · 3,290 participants · NA
Comparative Effectiveness of Prophylactic ICD Versus Non-ICD Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia